Patents by Inventor Ekaterina Romanovskaya-Romanko

Ekaterina Romanovskaya-Romanko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL INFLUENZA VIRUS
    Publication number: 20180016560
    Abstract: The present invention provides a novel influenza virus wherein both the NS and the PB1 gene segments are modified and wherein the PB1-F2 open reading frame is modified by introduction of at least one stop codon. Specifically, the influenza virus is lacking functional NS1 and PB1-F2 proteins. Additionally, a vaccine formulation comprising said modified influenza virus is provided and its use for prevention of influenza infection.
    Type: Application
    Filed: July 20, 2017
    Publication date: January 18, 2018
    Inventors: Thomas Muster, Ekaterina Romanovskaya-Romanko, Oleg Kiselev, Markus Wolschek, Boris Ferko, Andrej Egorov
  • Influenza virus
    Patent number: 9771564
    Abstract: The present invention provides a novel influenza virus wherein both the NS and the PB1 gene segments are modified and wherein the PB1-F2 open reading frame is modified by introduction of at least one stop codon. Specifically, the influenza virus is lacking functional NS1 and PB1-F2 proteins. Additionally, a vaccine formulation comprising the modified influenza virus is provided and its use for prevention of influenza vaccination.
    Type: Grant
    Filed: July 20, 2010
    Date of Patent: September 26, 2017
    Assignee: NANOTHERAPEUTICS, INC.
    Inventors: Thomas Muster, Ekaterina Romanovskaya-Romanko, Oleg Kiselev, Markus Wolschek, Boris Ferko, Andrej Egorov
  • NOVEL INFLUENZA VIRUS
    Publication number: 20120164175
    Abstract: The present invention provides a novel influenza virus wherein both the NS and the PB1 gene segments are modified and wherein the PB1-F2 open reading frame is modified by introduction of at least one stop codon. Specifically, the influenza virus is lacking functional NS1 and PB1-F2 proteins. Additionally, a vaccine formulation comprising said modified influenza virus is provided and its use for prevention of influenza infection.
    Type: Application
    Filed: July 20, 2010
    Publication date: June 28, 2012
    Applicant: AVIR GREEN BIOTECHNOLOGY RESEARCH DEVELOPMENT TRAD
    Inventors: Thomas Muster, Ekaterina Romanovskaya-Romanko, Oleg Kiselev, Markus Wolschek, Boris Ferko, Andrej Egorov